StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 7.0
Power Rank trend -> Falling
06/13/2025 16:10:00 EST
Edwards Lifesciences Corp (EW)
Industry: Medical Devices
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, EW has been trading in a range between $78.22 and $74.79 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
EW is trading below resistance at $78.22, about 4% to the upside. There is support at $74.79 -0% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Edwards Lifesciences Corp $EW entered a Green zone 3 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $80.9657, a potential upside of 7.74% from the recent price of 75.15. The stock is trading 26.75% (potential upside) below its 52 week high of $95.25 and 27.52 % (potential downside) above its 52 week low of $58.93 - based on the recent price.
Company Summary
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
News
| Edwards Lifesciences: With A Heart Beating Strong And Steady Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&P 500 averages. Source: Seeking Alpha Wed, 04 Jun 2025 14:11:11 -0400 Sentiment: Positive |
| How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems. Source: Investors Business Daily Wed, 28 May 2025 10:14:40 -0400 Sentiment: Neutral |
| Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes. Source: Zacks Investment Research Fri, 23 May 2025 09:55:13 -0400 Sentiment: Positive |
| Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco. Source: Business Wire Thu, 22 May 2025 02:30:00 -0400 Sentiment: Neutral |
| Trade Tracker: Bill Baruch buys Edwards Lifesciences Bill Baruch, founder & president at Blue Line Capital, joins CNBC's 'Halftime Report' to detail his latest buy. Source: CNBC Television Mon, 19 May 2025 14:13:37 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 95.25 52 Week Low: 58.93 Beta: 1.123 50 Day MA: 74.4484 200 Day MA: 71.3125 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0.042 Qtr Revenue Growth YOY: 0.062 Forward PE: 30.7692 Trailing PE: 31.0537